Predictive Oncology’s Wholly Owned Subsidiary Helomics announces the start of its drug repurposing project using its ground...
February 08 2021 - 7:30AM
Predictive Oncology (NASDAQ: POAI), a
knowledge-driven company focused on applying artificial
intelligence (“AI”) to personalized medicine and drug discovery,
announced today that it will start an in-house drug repurposing
project, focused on ovarian cancer, using its proprietary
AI-driven, patient centric discovery platform – PeDAL™. The project
will use PeDAL to rapidly and cost-effectively profile panel of
existing drugs against hundreds of patient cell lines. This process
will generate data on which compounds are active against which
specific patient profile(s), delivering both proof data for the
PeDAL approach and valuable Intellectual Property (IP) for the
company.
“With our Helomics division’s deep experience in
clinical profiling of patient tumor drug response, plus our unique
PeDAL platform, we have all the components to perform in-house drug
repositioning and even full drug discovery. We are very excited to
kick-off this first project focused on ovarian cancer. Our
expectations are that the project will have significant value by
generating proof data for our PeDAL approach, which will be useful
in our commercial discussions with Pharmaceutical companies. In
addition, the project will also demonstrate the long-term value of
Helomics unique data,” explained Dr. Carl Schwartz, CEO of
Predictive Oncology.
“Looking forward, we strongly believe successful
execution of this project will demonstrate that Predictive Oncology
is emerging as a leader in AI-driven drug discovery,” commented Dr.
Schwartz.
About Predictive Oncology Inc.
Predictive Oncology (NASDAQ: POAI) operates
through three segments (Skyline, Helomics and Soluble Biotech),
which contain four subsidiaries: Helomics, TumorGenesis, Skyline
Medical and Soluble Biotech.
Helomics applies artificial intelligence to its
rich data gathered from patient tumors to both personalize cancer
therapies for patients and drive the development of new targeted
therapies in collaborations with pharmaceutical companies.
TumorGenesis Inc. specializes in media that help cancer cells grow
and retain their DNA/RNA and proteomic signatures, providing
researchers with a tool to expand and study cancer cell types found
in tumors of the blood and organ systems of all mammals, including
humans. Skyline Medical markets its patented and FDA cleared
STREAMWAY System, which automates the collection, measurement, and
disposal of waste fluid, including blood, irrigation fluid and
others, within a medical facility, through both domestic and
international divisions. Soluble Biotech is a provider of soluble
and stable formulations for proteins including vaccines,
antibodies, large and small proteins, and protein complexes.
Forward-Looking Statements
Certain matters discussed in this release contain
forward-looking statements. These forward-looking statements
reflect our current expectations and projections about future
events and are subject to substantial risks, uncertainties and
assumptions about our operations and the investments we make. All
statements, other than statements of historical facts, included in
this press release regarding our strategy, future operations,
future financial position, future revenue and financial
performance, projected costs, prospects, plans and objectives of
management are forward-looking statements. The words “anticipate,”
“believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,”
“target” and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. Our actual future
performance may materially differ from that contemplated by the
forward-looking statements because of a variety of factors
including, among other things, factors discussed under the heading
“Risk Factors” in our filings with the SEC. Except as expressly
required by law, the Company disclaims any intent or obligation to
update these forward-looking statements.
Investor Relations Contact:
Landon Capital Keith Pinder (404)
995-6671kpinder@landoncapital.net
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Apr 2024 to May 2024
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From May 2023 to May 2024